AKERO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt SecuritiesIndenture • May 10th, 2024 • Akero Therapeutics, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSMAkero Therapeutics, Inc. • May 10th, 2024 • Pharmaceutical preparations
This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by Akero Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (“Agent”), that are parties to that certain Open Market Sale AgreementSM, dated March 17, 2023 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:
